Interactive Features

Quiz

Quiz: Amivantamab Outcomes vs Other Real-World Therapies for EGFR-Mutated NSCLC

07/25/2022

In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?

In the single-arm CHRYSALIS...

07/25/2022

Oncology

Quiz

Quiz: Does This Treatment for Patients With Brain Metastases Show High Efficacy?

03/10/2022

True or false: Osimertinib shows poor outcomes for asymptomatic brain metastases.

True or false: Osimertinib shows...

03/10/2022

Oncology

Test Your Knowledge

Quiz: Are Anti-EGF Vaccinations Effective for EGFR+ NSCLC?

02/14/2022

True or false: Anti-EGF vaccinations provide zero clinical benefit for EGFR+ NSCLC.

True or false: Anti-EGF...

02/14/2022

Oncology

Test Your Knowledge

Quiz: Does Ivonescimab Show Excellent Anti-Tumor Effects in NSCLC?

02/08/2022

True or false: Ivonescimab shows excellent anti-tumor effects in NSCLC.

True or false: Ivonescimab shows...

02/08/2022

Oncology

Test Your Knowledge

Quiz: Are EGFR-TKIs Viable With Chemo in Advanced NSCLC?

01/31/2022

True or false: EGFR-TKIs with chemo achieve clinical benefit in advanced NSCLC.

True or false: EGFR-TKIs with...

01/31/2022

Oncology

Test Your Knowledge

Quiz: Most EGFR+ Lung Cancer Mutations are Which of the Following?

01/28/2022

Almost all EGFR+ lung cancers are ________.

Almost all EGFR+ lung cancers...

01/28/2022

Oncology

Test Your Knowledge

Quiz: What is the Effect of Smoking History in EGFR-Mutated NSCLC?

09/13/2021

True or false: EGFR-mutant NSCLC mainly occurs in non-smoking patients, but most series report 10% of cases in current of previous smokers.

True or false: EGFR-mutant NSCLC...

09/13/2021

Oncology

Test Your Knowledge

Quiz: What is the Effect of Smoking History in EGFR-Mutated NSCLC?

09/13/2021

True or false: EGFR-mutant NSCLC mainly occurs in non-smoking patients, but most series report 10% of cases in current of previous smokers.

True or false: EGFR-mutant NSCLC...

09/13/2021

Oncology

Test Your Knowledge

Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?

08/03/2021

The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.

The combination of...

08/03/2021

Oncology

Test Your Knowledge

Quiz: Are CAR T-Cells Active Against EGFR+ Hypopharyngeal Carcinoma?

08/17/2020

True or False: EGFR-CAR T-cells produce anti-tumor activity in EGFR-positive hypopharyngeal carcinoma.

True or False: EGFR-CAR T-cells...

08/17/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology